CNBC May 23, 2024
Key Points
– Targeted radiopharmaceuticals has caught the eye of big pharma.
– The therapy delivers radiation directly into tumors by attaching a radioactive particle to a targeting molecule.
– RBC Capital Markets sees a $25 billion market opportunity for the space.
Big pharma is betting billions on an up-and-coming class of cancer treatments that some on Wall Street are calling a “massive opportunity.”
It’s called targeted radiopharmaceutical therapy. It essentially delivers radiation directly into tumors by attaching a radioactive particle to a targeting molecule.
RBC Capital Markets sees a $25 billion market opportunity for the space.
“We believe TRT development is still in its early stages, and next-generation technologies that enable improvements in therapeutic potency and address a wider...
Today's Sponsors
Today's Sponsor